admin

Maryland’s Department of Health announced Thursday it will partner with 13 hospitals around the state to launch an antibody study on unused blood samples. It’s part of a new program to incorporate antibody testing into the state’s continued strategy to fight COVID-19.

The News4 I-Team first asked about that strategy in May, when Virginia began posting its antibody testing details online, with positive and negative results listed by local health district. In mid-July, Maryland provided the I-Team with data showing more than 81,000 Marylanders had been antibody tested through private vendors.

GAITHERSBURG, MD, AUGUST 18, 2020 — MaxCyte, Inc., a global cell-based therapies and life sciences company, today announces the expansion of subsidiary CARMA Cell Therapies’ ongoing Phase I intraperitoneal delivery and dose-escalation trial of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate. The expansion will involve a new parallel cohort of patients and the initiation of two additional clinical sites.

The new parallel Phase I cohort will evaluate intraperitoneal delivery of MCY-M11 at escalating doses in additional patients with relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma, with the addition of a preconditioning regimen of cyclophosphamide prior to MCY-M11 infusion. This parallel Phase I cohort with preconditioning will progress independently from the ongoing evaluation of MCY-M11 in the existing no-preconditioning Phase I cohort. The MCY-M11 Phase I trial will also allow for multiple treatment cycles where indicated for both future preconditioning and no-preconditioning patients.

The biotechnology company Novavax will soon begin the second phase of human testing for its COVID-19 vaccine.

The so-called phase 2b clinical trial will include a group of 2,665 healthy adults in South Africa, as well as a group of 240 adults with HIV who are considered medically stable but whose immune responses may differ from individuals without HIV, according to a statement released by Novavax on Aug. 17. HIV advocacy groups have pushed for people with HIV to be included in clinical trials for COVID-19 vaccines, as companies like Moderna and Pfizer initially said they would exclude volunteers with the infection, Science Magazine reported. 

The coronavirus pandemic has impacted cities across the country with varying force. New York City has been hardest hit, and it’s no secret that the Big Apple is going to be one of the places that will have the most challenging time bouncing back from the coronavirus pandemic, no matter when things subside. But which cities will have the best coronavirus recovery? And which other cities will struggle? Moody’s Analytics has issued a report that examines the potential to recover from coronavirus among the top 100 metro areas in the US—and while some of the results are to be expected, some are more surprising.

GAITHERSBURG, Md., Aug. 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

The OrganoPlate® Graft is the first in vitro cell culture platform that allows vascularization of 3D tissues like spheroids, organoids, and tumors in vitro.

In this webinar, you will learn:

Limitations of current models How to build 3D vascularized tissues How to form vascular beds in vitro How to add 3D microtissues in the OrganoPlate Graft How to set up available assays How to get started in your lab

Image: https://go.mimetas.com

(Rockville, MD – August 20, 2020) –  Scheer Partners is proud to announce that 704 Quince Orchard Road, Gaithersburg, Maryland is 100% leased.

In 2018 Scheer Partners’ affiliate, South Duvall, part of a joint venture with a publicly traded REIT, acquired 704 Quince Orchard Road. 704 Quince Orchard Road presented an opportunity to convert an underperforming office building in the Gaithersburg Life Sciences Cluster. Scheer Partners, Inc. provided brokerage, construction management, and property management services for the 80,000 square foot project and made the entire building “lab-ready.” Scheer Partners’ Adnan Sheikh spearheaded construction management of the project in partnership with their Property Management Division, led by Ayesha Murray, which continues to ensure the building operates at peak performance.

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

Mayo Clinic is collaborating with APT to conduct a clinical trial using PhageBankTM investigational therapy to address the significant unmet need for alternative treatments for chronic infections following joint replacement (referred to as “periprosthetic joint infections,” or “PJIs”). Proceeds from the convertible note are designated to initiate the trial.

The cells that allow people to smell are a key entryway for the coronavirus, making nose coverings crucial, suggests new research from the Johns Hopkins University.

The nose already had been emerging as a main door for the virus and related respiratory disease. But this research specifically points to the olfactory cells because they have a very large number of receptors on their surface called ACE2 that have been shown to be vulnerable to coronaviruses.